Jakubowitz Law

NEW YORK, NY / ACCESSWIRE / July 21, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Virgin Galactic Holdings, Inc. (NYSE:SPCE)

CONTACT JAKUBOWITZ ABOUT SPCE:
https://claimyourloss.com/securities/virgin-galactic-holdings-inc-loss-submission-form/?id=17867&from=1

Class Period: October 26, 2019 - April 30, 2021

Lead Plaintiff Deadline: July 27, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) for accounting purposes, Social Capital Hedosophia Holdings Corp.'s ("SCH") warrants were required to be treated as liabilities rather than equities; (ii) Virgin Galactic had deficient disclosure controls and procedures and internal control over financial reporting; (iii) as a result, the Company improperly accounted for SCH warrants that were outstanding at the time of the business combination; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Ocugen, Inc. (NASDAQ:OCGN)

CONTACT JAKUBOWITZ ABOUT OCGN:
https://claimyourloss.com/securities/ocugen-inc-loss-submission-form/?id=17867&from=1

Class Period : February 2, 2021 - June 10, 2021

Lead Plaintiff Deadline: August 17, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Home Point Capital Inc. (NASDAQ:HMPT)

CONTACT JAKUBOWITZ ABOUT HMPT:
https://claimyourloss.com/securities/home-point-capital-inc-loss-submission-form/?id=17867&from=1

This lawsuit is on behalf of all persons and entities other than Defendants that purchased or otherwise acquired Home Point common stock pursuant and/or traceable to the Company's January 29, 2021 initial public offering.

Lead Plaintiff Deadline : August 20, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Home Point's aggressive expansion of its broker partners would dramatically increase the Company's expenses; (ii) the mortgage industry was anticipating industry-wide decreased gain-on-sale margins as a result of rising interest rates in 2021 and Home Point would be subject to the same competitive pressures; (iii) accordingly, the Company had overstated its business and financial prospects; and (iv) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

View source version on accesswire.com:
https://www.accesswire.com/656579/LAWSUITS-FILED-AGAINST-SPCE-OCGN-and-HMPT--Jakubowitz-Law-Pursues-Shareholders-Claims

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.